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Imepitoin has recently been registered for the management of dogs with idiopathic epilepsy (IE). Currently, there is no evidence- 
based information available on which antiepileptic drug (AED) to add to the treatment of dogs with IE that are not well controlled 
with imepitoin. 
The goal of this study was to evaluate the efficacy of phenobarbital (PB) or potassium bromide (KBr) as an add-on AED for 
controlling dogs refractory to a maximum dose of imepitoin. The study was performed as a prospective, randomized, controlled 
clinical trial. The efficacy of PB or KBr was evaluated by comparing monthly seizure frequency (MSF), monthly seizure day 
frequency (MSDF) and the presence of cluster seizures during a retrospective 2-month period with a prospective follow-up period 
of 6 months. Also the 50% responder rate (RR) was investigated. Twenty-seven dogs were included in the study, 14 dogs in the PB 
group and 13 dogs in the KBr group. A significant decrease in median MSF and MSDF was found in the PB group (P=0.001 and 
P=0.001, respectively) and in the KBr group (P=0.004 and P=0.003, respectively). Overall, the number of dogs with cluster seizures 
decreased significantly (P=0.0005). The RR was 79% vs. 69% in the PB and KBr group, respectively. 
We conclude that PB or KBr add-on treatment efficiently decreases median MSF and MSDF in dogs refractory to a maximum 
dose of imepitoin. Combination therapy was generally well tolerated and resulted in an improvement in seizure management in the 
majority of the dogs. 
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